Actos and its Associated Increased Risk of Bladder Cancer
According to an ongoing epidemiological study by the FDA, patients who take Actos for more than one year have an increased risk of bladder cancer. A warning was released just a few short days after France and Germany suspended sales of the antidiabetic drug. Studies revealed that patients who had the longest exposure to the drug and who had been consumed a cumulative dose were at the greatest risk for developing bladder cancer. According to a five-year analysis that included information from more than 193,000 diabetic patients who were treated with Actos for an average of two years it was discovered that:
- (1) patients who were on the drug for more than one year had a 40% increased risk of developing bladder cancer than patients who never took the drug and
- (2) patients who were on the drug for more than one year were associated with 27.5 excess cases of bladder cancer per 100,000 people, compared to people who never took Actos.
A study was conducted on August 17, 2011 regarding the side effects associated with taking Actos and the increased risk of bladder cancer. The study claims that 22,512 patients reported side effects when taking Actos and 0.22% of them have bladder cancer. Approximately 43% of patients with bladder cancer report to have taken Actos between two and five years, with the second largest concentration of those afflicted with bladder cancer reported to have taken Actos for just one to six months.